The Drug Supply Chain Security Act (DSCSA) is a federal law enacted by the United States Congress in 2013. The objective of the act is to ensure that the drug supply chain is secure and safe from counterfeit, diverted, or stolen drugs. The DSCSA requires all companies in the drug supply chain to comply with certain requirements and regulations. Companies that do not comply with the DSCSA requirements can face penalties, including fines and civil liabilities.
The DSCSA requires pharmaceutical companies to put in place systems and processes to ensure the security of the drug supply chain. This includes systems to identify, track, and trace prescription drugs. Pharmaceutical companies must also establish procedures to investigate and respond to supply chain security incidents. In addition, they must maintain records of supply chain activities and report suspicious activities to the US Food and Drug Administration (FDA).
What are the 2023 DSCSA Requirements?
The 2023 DSCSA requirements include a number of measures that pharmaceutical companies must meet in order to comply with the law. These requirements include:
- Identifying and tracking drugs from the manufacturer to the patient.
- Establishing procedures to investigate and respond to supply chain security incidents.
- Maintaining records of supply chain activities.
- Reporting suspicious activities to the FDA.
- Filing reports to the FDA within specific timelines.
- Establishing systems to detect and investigate supply chain security threats.
- Developing systems to verify the identity of drug products.
- Participating in the FDA’s product tracing pilot program.
- Creating a system to collect, store, and exchange product tracing information.
- Complying with the FDA’s requirements for product tracing information.
The 2023 DSCSA requirements also include the implementation of a number of systems and processes to ensure the security of the drug supply chain. These include:
- Establishing systems to detect and investigate supply chain security threats.
- Developing systems to verify the identity of drug products.
- Implementing systems to capture and exchange product tracing information.
- Creating systems to collect, store, and exchange product tracing information.
- Complying with the FDA’s requirements for product tracing information.
What Are the Penalties for Non-Compliance with the 2023 DSCSA Requirements?
Companies that do not comply with the 2023 DSCSA requirements can face penalties, including fines and civil liabilities. The FDA may also revoke the company’s registration or suspend the sale of its products. Companies that are found to be in violation of the DSCSA requirements may also be subject to criminal prosecution.
Conclusion
The 2023 DSCSA requirements are a set of measures that pharmaceutical companies must meet in order to comply with the law. These requirements include identifying and tracking drugs from the manufacturer to the patient, establishing procedures to investigate and respond to supply chain security incidents, and reporting suspicious activities to the FDA. Companies that do not comply with the 2023 DSCSA requirements can face penalties, including fines and civil liabilities.